Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067958 | 0.83 | KDM4E (0.55) | MAPK1PTGS2SLC9A1SLC9A2KDM4E | |
| SCHEMBL12310543 | 0.83 | MAPK1 (0.51) | MAPK1PTGS2LMNANPSR1SLC9A1 | |
| SCHEMBL3841619 | 0.72 | MAPK1 (0.58) | MAPK1PTGS2GRM4SLC9A1SLC9A2 | |
| SCHEMBL27544115 | 0.72 | ALDH1A1 (0.47) | PTGS2LMNANPSR1NPC1RAB9A | |
| SCHEMBL3007153 | 0.71 | KDM4E (0.71) | MAPK1LMNANPSR1KDM4EPOLB | |
| SCHEMBL1501094 | 0.71 | GAA (0.41) | MAPK1LMNANPSR1KDM4EPOLB | |
| SCHEMBL14188153 | 0.70 | MAPK1 (0.56) | MAPK1PTGS2GRM4SLC9A1SLC9A2 | |
| SCHEMBL10139089 | 0.70 | MAPK1 (0.51) | MAPK1PTGS2GRM4SLC9A1SLC9A2 | |
| SCHEMBL12806554 | 0.70 | SMO (0.59) | MAPK1PTGS2NPSR1SLC9A1SLC9A2 | |
| SCHEMBL3517559 | 0.70 | MAPK1 (0.73) | MAPK1PTGS2LMNASLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8859814-B2 | Alpha-substituted N-sulfonyl gylcine amides antagonists of CCR10, compositions containing the same and methods for using them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2294051-B1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| EP-1892239-B1 | Inhibitors of cytosolic phospholipase A2 | WYETH LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20110275612-A1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-7910742-B2 | Survivin inhibitors | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20060014759-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005121145-A2 | OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| US-6797708-B2 | ENZYME INHIBITORS SUCH AS 4-(2-(1-BENZHYDRYL-2-(2-((BENZYL-SULFONYL)AMINO)ETHYL)-5-CHLORO-1H-INDOL-3 -YL)ETHOXY) BENZOIC ACID, USED AS ANALGESICS OR ANTIINFLAMMATORY AGENTS | WYETH | 2004-09-28 | — | — | US | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275612-A1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | CCR10, CCR1, CCR3 | MAPK1 1888/4885PTGS2 4054/4885LMNA 2661/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | MAPK1 1656/4885PTGS2 676/4885LMNA 2594/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | MAPK1 1663/4885PTGS2 28/4885LMNA 2777/4885 |
| US-20060014759-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G1B | MAPK1 1566/4885PTGS2 21/4885LMNA 1740/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | MAPK1 2004/4885PTGS2 20/4885LMNA 2545/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | MAPK1 1237/4885PTGS2 28/4885LMNA 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.